Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo VYNE Therapeutics Inc.
Vyne Therapeutics Inc. is a specialty pharmaceutical company. The Company is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The CompanyÔÇÖs proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.

Number of employees : 106 people.
Sales per Business
2020
Topical Minocycline Products10.2048.6%
License10.0047.6%
Royalty0.793.8%
USD in Million
Sales per region
20192020Delta
United States--20.99100%-
USD in Million
Managers
Name Title Age Since
David Domzalski President, Chief Executive Officer & Director 54 2020
Tyler Zeronda Chief Financial Officer & Treasurer 35 2021
Iain A. Stuart, Dr. Chief Scientific Officer 48 -
Sharon Barbari Independent Director 66 2020
Steven L. Basta Independent Director 55 2015
Rex Bright Independent Director 81 2020
Anthony D. Bruno Independent Director 65 2020
Elisabeth A. Sandoval Independent Director 59 2019
Patrick G. LePore Lead Independent Director 66 2020
Mutya Harsch Secretary, Chief Legal Officer & General Counsel 46 2020
Members of the board
Name Title Age Since
David Domzalski President, Chief Executive Officer & Director 54 2020
Sharon Barbari Independent Director 66 2020
Steven L. Basta Independent Director 55 2015
Rex Bright Independent Director 81 2020
Anthony D. Bruno Independent Director 65 2020
Elisabeth A. Sandoval Independent Director 59 2019
Patrick G. LePore Lead Independent Director 66 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 53,517,912 49,569,604 92.6% 0 0.0% 92.6%
Shareholders
NameEquities%
The Vanguard Group, Inc. 2,408,220 4.50%
Perceptive Advisors LLC 2,330,471 4.35%
Franklin Advisers, Inc. 1,921,236 3.59%
Renaissance Technologies LLC 1,245,027 2.33%
DSC Advisors LP 1,100,000 2.06%
Medical Strategy GmbH 864,989 1.62%
BlackRock Fund Advisors 806,012 1.51%
683 Capital Management LLC 715,386 1.34%
SSgA Funds Management, Inc. 544,013 1.02%
Cabot ETF Partners LLC 478,937 0.89%
Brand Portfolio
In partnership withAllbrands.markets
More brands of VYNE Therapeutics Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-38.24%34
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356
NOVO NORDISK A/S-14.11%219 146
MERCK & CO., INC.4.36%202 025
NOVARTIS AG-0.51%195 853
ASTRAZENECA PLC0.85%183 867
BRISTOL-MYERS SQUIBB COMPANY3.58%141 036
SANOFI2.66%129 475
AMGEN INC.1.22%128 267
GLAXOSMITHKLINE PLC2.53%112 384
BAYER AG9.83%57 517
CHUGAI PHARMACEUTICAL CO., LTD-1.47%53 179
TAKEDA PHARMACEUTICAL COMPANY LIMITED5.93%45 488
JIANGSU HENGRUI MEDICINE CO., LTD.-11.38%45 167
DAIICHI SANKYO CO., LTD.-10.80%43 949
ASTELLAS PHARMA INC.3.37%31 486
YUNNAN BAIYAO GROUP CO.,LTD-6.82%19 730